Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CHDR, will conduct and manage the proposed clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aim ImmunoTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 29, 2021